Peculiarities of the Course and Approaches to the Treatment of HPV-Associated Vulvar Cancer in HIV-Positive Women
Bulletin of the Asian International University named after Satkynbai Tentishev · 2026-04 · 2 (1) · 128-134
DOI: 10.65691/aiust.v2.i1.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of the Asian International University named after Satkynbai Tentishev, 2026-04. Verfasst von A.K. Moldobekova.
Abstract (Originalsprache)
Relevance. HPV-associated vulvar cancer presents a significant oncological challenge, with substantially higher risk among women living with HIV.
Objective
To systematize clinical and morphological data and evaluate treatment approaches in the HAART era. Materials and Methods. Literature in PubMed, Scopus, and Web of Science from 2015-2025 was systematically analyzed.
Results
HIV-positive women are diagnosed at a younger average age; with adequate CD4 and viral-load control, survival with HAART may approach that of HIV-negative patients, while advanced-stage management remains insufficiently standardized.
Conclusion
Early diagnosis and multidisciplinary management are essential.
Zitieren
APA
Moldobekova, A. (2026). Peculiarities of the Course and Approaches to the Treatment of HPV-Associated Vulvar Cancer in HIV-Positive Women. Bulletin of the Asian International University named after Satkynbai Tentishev, 2(1), 128-134. https://doi.org/10.65691/aiust.v2.i1.012
Vancouver
Moldobekova A. Peculiarities of the Course and Approaches to the Treatment of HPV-Associated Vulvar Cancer in HIV-Positive Women. Bulletin of the Asian International University named after Satkynbai Tentishev. 2026;2(1):128-134. doi:10.65691/aiust.v2.i1.012
BibTeX
@article{Moldobekova2026,
author = {Moldobekova, A.K.},
title = {Peculiarities of the Course and Approaches to the Treatment of HPV-Associated Vulvar Cancer in HIV-Positive Women},
journal = {Bulletin of the Asian International University named after Satkynbai Tentishev},
year = {2026},
volume = {2},
number = {1},
pages = {128--134},
doi = {10.65691/aiust.v2.i1.012}
}
EUVIMED